Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology.
AuthorsPaller, Amy S
Irvine, Alan D
de Bruin-Weller, Marjolein
Ozturk, Zafer E
MetadataShow full item record
AbstractIntroduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease often associated with atopic comorbidities and has significant impact on children and their families. There is a lack of robust and longitudinal long-term data on disease characteristics and typical clinical practice with currently available treatments in children with moderate-to-severe AD. Hence, an observational study is needed to evaluate AD characteristics and progression in paediatric patients with moderate-to-severe AD. Methods and analysis: Pediatric Study in Atopic Dermatitis (PEDISTAD) is a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe AD who are currently receiving systemic or topical treatment and whose disease is not adequately controlled by topical prescription therapies or for whom those therapies are not medically advisable. 1300 children at 100-150 sites in approximately 20 countries worldwide will be enrolled and followed for 5 years. AD therapy is at the discretion of the investigator. Data collected will include: AD disease characteristics and comorbidities; current therapy for AD and initiation of new treatments/changes in current treatment; patient-reported/caregiver-reported outcomes; days missed from school/work for the patient/caregiver; healthcare professional visits; safety and biomarkers. Ethics and dissemination: This study is conducted in accordance with the principles established by the 18th World Medical Assembly and all subsequent amendments and the guidelines for Good Epidemiology Practice. Each individual country assures that ethics approval has been received and local regulatory requirements are met. Ethics approval has been obtained in all countries currently participating in PEDISTAD. Study data will be disseminated in manuscripts submitted to peer-reviewed medical journals as well as in abstracts submitted to congresses and in the resulting posters and presentations.
- Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial.
- Authors: van Halewijn KF, Bohnen AM, van den Berg PJ, Pasmans SGMA, Bindels PJE, Elshout G
- Issue date: 2019 Jun 19
- Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol.
- Authors: de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C
- Issue date: 2020 Sep 16
- International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale.
- Authors: Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, Thaçi D, Guttman-Yassky E
- Issue date: 2020 Nov 27
- Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
- Authors: Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, Tajima Y, Ardeleanu M, Rizova E, Arima K, ADDRESS-J Investigators
- Issue date: 2019 Apr
- TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
- Authors: Bosma AL, Spuls PI, Garcia-Doval I, Naldi L, Prieto-Merino D, Tesch F, Apfelbacher CJ, Arents BWM, Barbarot S, Baselga E, Deleuran M, Eichenfield LF, Gerbens LAA, Irvine AD, Manca A, Mendes-Bastos P, Middelkamp-Hup MA, Roberts A, Seneschal J, Svensson Å, Thyssen JP, Torres T, Vermeulen FM, Vestergaard C, von Kobyletzki LB, Wall D, Weidinger S, Schmitt J, Flohr C
- Issue date: 2020 Jun